Venus Remedies Share Price Today

Venus Remedies declares ₹10 dividend, appoints Saransh Chaudhary as ED

Venus Remedies declared a final dividend of ₹10 per equity share for FY26. All 12 AGM resolutions passed, including adoption of audited financials. Saransh Chaudhary appointed as Executive Director for a five-year term. New Articles of Association adopted to align with Companies Act, 2013. Public institutions showed dissent on some board appointments and AOA changes.

Venus Remedies AGM to approve ₹10 dividend, new board appointments

Venus Remedies Limited convenes its 37th AGM on August 20, 2026, to approve a ₹10 dividend, marking the first payout in over a decade. The meeting also finalizes the appointment of Saransh Chaudhary as Executive Director and the re-appointment of Dr. (Mrs.) Manu Chaudhary as Joint Managing Director, alongside updates to the MOA and AOA.

Venus Remedies Q1 net profit rises 118% to ₹22.97 crore

Venus Remedies reported a 118% surge in consolidated net profit to ₹22.97 crore for Q1FY26, driven by a 30.4% rise in revenue to ₹178.86 crore and significant margin expansion. The board approved the unaudited results and revisions to the Memorandum of Association to align with the Companies Act, 2013. Auditors flagged outstanding share application money of ₹2,859.72 lakhs in subsidiary Venus Pharma GmbH, which reported a net loss for the quarter.

Venus Remedies declares ₹10 final dividend for FY26

Venus Remedies Limited has recommended a final dividend of ₹10 per share for FY26, with a record date of August 7, 2026. The 37th AGM is scheduled for August 20, 2026, via video conferencing. Dividends will be paid electronically within 30 days of the AGM, subject to TDS.

Venus Remedies FY26 net profit surges 89% to ₹102.78 crore

Venus Remedies reported a consolidated net profit of ₹102.78 crore for FY26, a significant increase from ₹45.31 crore in the previous year, driven by a rise in revenue to ₹769.60 crore. The board recommended a final dividend of ₹10 per share and approved the re-appointment and appointment of several directors, including Dr. (Mrs.) Manu Chaudhary and Mr. Saransh Chaudhary.

Venus Remedies Receives Saudi FDA Approval for Plerixafor in First Global Marketing Authorization for Specialty Cancer Treatment

Venus Remedies has received marketing approval from the Saudi Food and Drug Authority (Saudi FDA) for Plerixafor, a specialty cancer treatment. This approval marks the company's first global marketing authorization for this product. The regulatory clearance enables Venus Remedies to commercialize Plerixafor in the Saudi Arabian market and represents a significant milestone in its oncology portfolio.